Reach Us +1-504-608-239
Editor - Giuseppe Badalamenti | University of Palermo | 22350
ISSN: 2577-0535

Journal of Cancer Clinical Trials
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Relevant Topics

Giuseppe Badalamenti

Giuseppe Badalamenti
Giuseppe Badalamenti
Principal Investigator
University of Palermo
University of Palermo


Dr. Giuseppe Badalamenti was born in Mirano (Venice) in 1974. He studied at the University Medical School of Palermo (Italy) and received his MD degree in 1999. He earned the post-graduate specialty in Medical Oncology in 2003. In 2006 he obtained PhD in Clinical, Exprimental Oncology and Tumor Morphology at the University of Palermo. He got a scholarship with the prestigius Dr. Luca Gianni for breast cancer and with Dr. Paolo Casali for rare cancer at the National Cancer Institute of Milan. His research field is rare cancer, in particular soft tissue sarcomas, gastrointestinal stromal tumors and neuroendocrine tumors. Dr. Badalamenti is a active member of the National Rare Cancer Network, Clinical Coordinator of the Sicily Regional Rare Cancer Network, Executive Member of “Italian Sarcoma Group” and author of the Italian guidelines of Soft Tissue Tumors. He is principal investigator in several national and international clinical trials, according to Good Clinical Practice, specifically on rare tumors and he is a member of many tumor board to development new drugs in rare cancer.

Research Interest

Rare cancer, in particular soft tissue sarcomas, gastrointestinal stromal tumors and neuroendocrine tumors.


Soft Tissue Sarcomas

Giuseppe Badalamenti
Editorial: J Cancer Clin Trials 2016, 1:e106
Leave Your Message 24x7